All influenza vaccines marketed in the UK for the 2024 to 2025 season (text version)
Updated 21 March 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk/all-influenza-vaccines-marketed-in-the-uk-for-the-2022-to-2023-season
| Supplier | Name of product | Vaccine type | Age indications | Ovalbumin content micrograms per dose | Contact details |
|---|---|---|---|---|---|
| AstraZeneca UK Ltd | Fluenz® Tetra [footnote 1] | Quadrivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension | From 24 months to less than 18 years of age | Less than 0.024 micrograms per 0.2 ml dose | 0845 139 0000 |
| Sanofi | Quadrivalent influenza vaccine | QIVe (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated | From 6 months | Equal to or less than 0.05 micrograms per 0.5 ml dose. Need to confirm with company | 0800 854 430 |
| Viatris | Influvac® sub-unit Tetra | QIVe (standard egg-grown quadrivalent influenza vaccine), surface antigen, inactivated | From 6 months | Equal to or less than 0.1 micrograms per 0.5 ml dose | 0800 358 7468 |
| CSL Seqirus UK | Cell-based quadrivalent influenza vaccine Seqirus▾ | QIVc (cell-based quadrivalent influenza vaccine), surface antigen, inactivated | From 6 months | Egg-free | 08457 451 500 |
| Sanofi | Supemtek▾ | QIVr (quadrivalent influenza vaccine (recombinant, prepared in cell culture)) | From 18 years | Egg-free | 0800 854 430 |
| CSL Seqirus UK | Adjuvanted quadrivalent influenza vaccine Seqirus▾ | aQIV (adjuvanted egg-grown quadrivalent influenza vaccine) surface antigen, inactivated, adjuvanted with MF59C.1 | From 65 years | Equal to or less than 1 micrograms per 0.5 ml dose | 08457 451 500 |
The inverted Black Triangle symbol (▼) is used when a drug or vaccine is being monitored under the Black Triangle Scheme.
-
An alternate product formulation may be supplied in the 2024 to 2025 season; potential formulations for 2024 to 2025 season will have the same ovalbumin content threshold of ‘less than 0.024 micrograms per 0.2ml dose’. ↩